Vekthåndtering-behandlinger
Se tilgjengelige vekthåndtering-behandlinger. Alle inkluderer en uavhengig EU-legegjennomgang, ekte medisin fra lisensierte apotek og diskret ekspresslevering.
Vekthåndtering
Ozempic (Semaglutide)
Ozempic (semaglutide) is a once-weekly injectable medication for weight management and blood sugar control. It works by mimicking a natural hormone that regulates appetite and food intake, helping you feel fuller for longer.
Tenuate Retard (Amfepramon)
Tenuate Retard is a prescription appetite suppressant used as part of a weight management program. It helps reduce appetite and increase metabolism, making it easier to follow a reduced-calorie diet. Should be used alongside diet and exercise.
Xenical (Orlistat)
Xenical (orlistat) is a weight-loss medication that works by blocking fat absorption in your digestive system. Should be used as part of a comprehensive weight management program including a low-fat diet and exercise.
Interested in Vekthåndtering?
Complete a confidential health assessment reviewed by an independent EU-registered doctor.
Start AssessmentWeight management treatments in Europe
Excess weight and obesity represent one of the most significant public health challenges across the European Union. According to the World Health Organization, more than half of adults in the WHO European Region are overweight, and approximately 23% live with obesity. The health consequences extend well beyond aesthetics: obesity is a chronic condition associated with type 2 diabetes, cardiovascular disease, hypertension, sleep apnoea, and certain cancers.
For many people, lifestyle interventions — dietary changes and increased physical activity — are the foundation of weight management. However, clinical evidence consistently shows that for individuals with a BMI of 30 or above, or 27 or above with weight-related health conditions, prescription medications can provide meaningful additional benefit when used alongside lifestyle modifications.
The past decade has seen a significant advancement in the pharmacological options available for weight management in Europe. The approval of GLP-1 receptor agonists by the European Medicines Agency (EMA) has given doctors access to medications with demonstrated efficacy: clinical trials published in the New England Journal of Medicine show that semaglutide (the active ingredient in both Ozempic and Wegovy) produced an average weight reduction of approximately 15% of body weight over 68 weeks in adults with obesity. This represents a step-change compared to older weight management medications.
It is important to understand that prescription weight management medications are not a substitute for lifestyle changes, and they are not appropriate for everyone. All prescribing decisions must be made by a qualified, independent doctor based on a thorough assessment of each individual’s clinical circumstances.
Available treatments
The following prescription medications are available for weight management through EU-registered doctors. This comparison is provided for informational purposes only. A doctor will assess which medication, if any, is appropriate for your individual situation.
| Medication | Active Ingredient | Form | Typical Dose Range | EMA-Approved Indication |
|---|---|---|---|---|
| Ozempic | Semaglutide | Weekly injection | 0.5 mg–2 mg/week | Type 2 diabetes (also used off-label for weight management) |
| Wegovy | Semaglutide | Weekly injection | Up to 2.4 mg/week | Chronic weight management |
| Saxenda | Liraglutide | Daily injection | Up to 3 mg/day | Chronic weight management |
Key distinctions:
- Ozempic vs Wegovy: Both contain semaglutide, a GLP-1 receptor agonist. Ozempic carries EMA approval for type 2 diabetes management; Wegovy is the formulation approved specifically for chronic weight management at a higher maximum dose. Clinical data indicates that the higher semaglutide dose in Wegovy produces greater average weight loss.
- Saxenda: Contains liraglutide, a different GLP-1 receptor agonist requiring daily rather than weekly injections. Clinical head-to-head evidence suggests semaglutide achieves greater mean weight reduction than liraglutide over comparable treatment periods.
- Starting price: Prices vary by country, pharmacy, and dosage. Use the links above to see indicative starting prices for each medication through Prescrivia’s platform.
How to get weight management treatment online
Prescrivia operates as a technology intermediary. We do not prescribe medications, employ doctors, or sell medicines. Our platform connects patients across Europe with independent EU-registered doctors and licensed pharmacies.
The process:
-
Complete a health assessment — Answer a structured set of medical questions covering your health history, current medications, BMI, and weight management goals. The assessment is designed to give the reviewing doctor a thorough clinical picture.
-
Independent doctor review — An independent EU-registered doctor reviews your assessment. If a prescription medication is clinically appropriate for you, the doctor may issue a prescription. If it is not appropriate — due to contraindications, insufficient clinical indication, or other factors — the doctor will explain the reasoning.
-
Pharmacy fulfilment — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The pharmacy dispenses the medication and arranges delivery directly to your address.
Important: Prescrivia does not guarantee that a prescription will be issued. Prescribing decisions are made entirely by independent medical professionals. All medications are prescription-only medicines (POMs) in EU member states and require a valid prescription from a licensed doctor.
How we compare
| Through Prescrivia | In-person GP appointment | |
|---|---|---|
| Availability | 24/7 online assessment | Subject to appointment availability |
| Wait time | Assessment reviewed within hours | Days to weeks depending on location |
| Travel required | No | Yes |
| Prescribing decision | Made by independent EU-registered doctor | Made by your GP |
| Ongoing monitoring | Supported via follow-up assessments | Managed by your GP |
| Cost | Transparent pricing displayed upfront | Varies by country and healthcare system |
Note: For patients with complex medical histories, multiple comorbidities, or conditions requiring close clinical monitoring, an in-person consultation with a GP or specialist may be more appropriate. Prescrivia’s platform is designed for adults who meet the clinical criteria for prescription weight management medications and whose health profile is suitable for remote assessment.
Sources
Medical information on this page is based on the following sources:
- European Medicines Agency (EMA). Wegovy (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
- European Medicines Agency (EMA). Saxenda (liraglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
- World Health Organization (WHO). Obesity and overweight in the WHO European Region — Fact sheet. euro.who.int
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.
Frequently asked questions
- Can I get weight loss medication online in Europe?
- Yes, you can access weight management medications through online intermediary platforms that connect you with independent EU-registered doctors. A doctor will assess whether treatment is clinically appropriate based on your health profile.
- Do I need a BMI of 30 to qualify for weight loss medication?
- Eligibility depends on the specific medication and clinical guidelines. Generally, GLP-1 medications are considered for patients with a BMI of 30+ (obese) or 27+ (overweight) with weight-related comorbidities. The prescribing doctor makes the final determination.
- How much weight can I lose with prescription weight management medication?
- Clinical trials show that GLP-1 receptor agonists like semaglutide can lead to an average weight reduction of 12-15% of body weight over 68 weeks, though individual results vary significantly.
- Are weight management medications safe?
- EMA-approved weight management medications have undergone extensive clinical trials. Common side effects include gastrointestinal symptoms that typically diminish over time. A qualified doctor will assess whether the benefits outweigh the risks for your individual situation.
- What is the difference between Ozempic and Wegovy?
- Both contain semaglutide, but Ozempic is approved for type 2 diabetes while Wegovy is specifically approved for weight management at a higher dose (2.4mg vs 2mg). Your doctor will determine which is most appropriate.
Klar til å komme i gang?
Fullfør en konfidensiell helsevurdering på omtrent 3 minutter.